CoChat

The DOI matches its Crossref record; 91 of the 95 references it cites were found in a registry or an index; 93 of the 201 sources its claims cite were checked for support.

Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions

Open access
Zorkina, Yana, Abramova, Olga, Zubkov, Eugene, Gurina, Olga, Ushakova, Valeriya · 2026 · International Journal of Molecular Sciences

Abstract

This critical review identifies pharmacokinetic, dose, and temporal conflicts that hinder the translation of theranostic nanoplatforms for AD.

Overview

CoChat Summary

## TL;DR

This is a critical review arguing that current Alzheimer’s disease theranostic nanoplatforms are constrained by three fundamental conflicts: pharmacokinetic, dose, and temporal mismatches. The authors conclude that the “one particle for everything” model has not translated clinically and recommend alternative strategies such as preclinical “hit-and-clear” intervention, separate diagnostic/therapeutic particles, and theranostic monitoring.

## Key findings

  • The review identified three core conceptual conflicts in AD theranostics:
  • Pharmacokinetic conflict: diagnostics need rapid accumulation and clearance, while therapy needs prolonged retention.
  • Dose conflict: diagnostic and therapeutic doses often differ by orders of magnitude; the paper states 13–400-fold or greater disparities, and in one example diagnostic and therapeutic doses for SPIONs were reported as 5860 mg/kg vs 25–100 mg/kg.
  • Temporal conflict: imaging is typically short-term, but AD therapy is chronic/lifelong, making repeat diagnostics difficult because particles can generate persistent background signals.
  • The authors say only 23 studies were selected for their representative analysis of existing nanotheranostic systems for AD.
  • Brain delivery is reported as very limited in the few studies with quantitative data, with accumulation of only 1.94% ID/g for a nanosweeper system and 1.12–1.57% ID/g for mesoporous NPs with dual targeting.
  • The paper highlights a methodological trap: much of the field focuses on mature Aβ fibrils, even though the authors argue soluble Aβ oligomers are the more toxic species and should be prioritized.

## Methods

  • This is a critical review, not a systematic review; the authors explicitly say they chose a conceptual analysis rather than an exhaustive catalog.
  • They performed a literature search in PubMed, Scopus, and Web of Science covering January 2015 to December 2024, using AD/nanomedicine/theranostic keywords.
  • Inclusion criteria: original peer-reviewed research on AD nanoplatforms with dual diagnostic and therapeutic functionality in in vitro or in vivo models; exclusion criteria included diagnosis-only, therapy-only, reviews, conference abstracts, editorials, book chapters, and non-AD neurodegenerative studies.

## Limitations

  • The authors state the sample was selective rather than exhaustive, because the goal was conceptual analysis rather than complete coverage.
  • They note that heterogeneous experimental models, dosing protocols, efficacy measures, and units prevent correct quantitative comparison across studies.
  • They also acknowledge that negative results are often not publicly available, which may distort the apparent success of approaches.
  • Evident from the text: many conclusions rest on a small set of representative studies, and several cited studies are preclinical only, often in models such as transgenic mice or *C. elegans*, limiting direct clinical inference.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms27083560

Cites

91 of 95 references verified0 citation errors · 4 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Molecular targets for theranostic intervention in AD for future clinical application. PET—positron emission tomography, MRI—magnetic resonance imaging. Created in Biorender. Zorkina, Y. (2026) https://BioRender.com/ry8uv36 (accessed on 27 March 2026).
Figure 1 Molecular targets for theranostic intervention in AD for future clinical application. PET—positron emission tomography, MRI—magnetic resonance imaging. Created in Biorender. Zorkina, Y. (2026) https://BioRender.com/ry8uv36 (accessed on 27 March 2026).CC BY · PubMed Central
Figure 2 Three inherent conflicts of theranostic platforms in AD and potential strategies to address them. The figure summarizes the fundamental contradictions that arise when attempting to combine diagnostic and therapeutic functions in a single nanoplatform. Pharmacokinetic Conflict: Arises from opposing requirements for rapid accumulation and clearance (diagnostics) versus prolonged presence and sustained release (therapy). This is compounded by the extremely low fraction of the dose reaching the brain (1–2% ID/g), while the vast majority accumulates in peripheral organs (98–99% ID/g), creating a risk of systemic toxicity. Dose Conflict: Reflects the discrepancy between the low doses sufficient for sensitive detection (minimal for detection) and the high doses required for a therapeutic effect (maximal for effect). Temporal Conflict: Highlights the incompatibility between single or short-term diagnostic interventions and the need for chronic, lifelong therapy. A single diagnostic peak can be obscured by background noise from accumulated particles, and the diagnostic window itself is unstable due to the dynamic nature of the BBB over the course of the disease. Resolving strategies are shown below each conflict: External triggers (near infrared (NIR) irradiation, magnetic field, pH, ROS) can separate diagnostic and therapeutic functions in time. High-risk AD subtypes (rapidly progressive/genetic) shift the risk/benefit balance, justifying higher-risk interventions. Preclinical stage offers a window for single, time-limited interventions. Theranostic monitoring involves sequential diagnosis, therapy, and re-assessment. Theranostic pairs (conceptual) propose using two particles with a shared ligand, each optimized for its task. Some icons in this figure were adapted from BioArt (https://bioart.niaid.nih.gov).
Figure 2 Three inherent conflicts of theranostic platforms in AD and potential strategies to address them. The figure summarizes the fundamental contradictions that arise when attempting to combine diagnostic and therapeutic functions in a single nanoplatform. Pharmacokinetic Conflict: Arises from opposing requirements for rapid accumulation and clearance (diagnostics) versus prolonged presence and sustained release (therapy). This is compounded by the extremely low fraction of the dose reaching the brain (1–2% ID/g), while the vast majority accumulates in peripheral organs (98–99% ID/g), creating a risk of systemic toxicity. Dose Conflict: Reflects the discrepancy between the low doses sufficient for sensitive detection (minimal for detection) and the high doses required for a therapeutic effect (maximal for effect). Temporal Conflict: Highlights the incompatibility between single or short-term diagnostic interventions and the need for chronic, lifelong therapy. A single diagnostic peak can be obscured by background noise from accumulated particles, and the diagnostic window itself is unstable due to the dynamic nature of the BBB over the course of the disease. Resolving strategies are shown below each conflict: External triggers (near infrared (NIR) irradiation, magnetic field, pH, ROS) can separate diagnostic and therapeutic functions in time. High-risk AD subtypes (rapidly progressive/genetic) shift the risk/benefit balance, justifying higher-risk interventions. Preclinical stage offers a window for single, time-limited interventions. Theranostic monitoring involves sequential diagnosis, therapy, and re-assessment. Theranostic pairs (conceptual) propose using two particles with a shared ligand, each optimized for its task. Some icons in this figure were adapted from BioArt (https://bioart.niaid.nih.gov).CC BY · PubMed Central

Verification

Claims the paper makes

65 Valid · 7 Not valid · 54 Not checked · 103 Own results and interpretations

118 more claims · 34 with their cited sources checked

Create a free account to see all 229 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 93
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Citations

Cites

Show all 95 references

Cited by

  • Targeted nanomedicine strategies for Alzheimer’s disease therapy

    Ardah, M. T., Yaseen, B. M., Malathi, H., Ray, S., Thyagarajan, R., Shankhyan, A., Eshmetov, R., Ataullaev, Z., & Mishra, M. K. (2026) · Discover Nano · doi:10.1186/s11671-026-04763-8 · Cited by 3

    “In late-stage dementia, amyloid-only strategies are less likely to restore function unless paired with interventions that address Tau pathology, neuroinflammation, synaptic loss, mitochondrial injury, or neurovascular dysfunction [162, 163].”

See all 1

Metadata

Authors
Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V.
Affiliations
Federal Medical Research Centre for Psychiatry and Narcology (RU)
Corresponding author
Zorkina, Yana
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2026-04-16
Volume
27
Issue
8
Pages
3560
ISSN
1422-0067 (ISSN-L)
OpenAlex
W7154576422
Cited by
1
References
95
Citations by year
2026: 1
FWCI
1.04
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
Russian Science Foundation (25-75-10063)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
Alzheimer's disease, theranostics, nanoplatforms, clinical translation, pharmacokinetics, temporal conflict, amyloid-beta oligomers, stimuli-responsive nanoparticles, brain drug delivery
MeSH terms
Theranostic Nanomedicine, Alzheimer Disease, Animals, Humans, Amyloid beta-Peptides, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions. https://app.cochat.ai/papers/10.3390/ijms27083560
The paper
Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V. (2026). Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27083560

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.